Optimal fractionation in radiotherapy for non-small cell lung cancer - A modelling approach

Acta Oncologica

Volumn 54, Issue 9, 2015, Pages 1592-1598

  Lindblom, Emely ^a   Dasu, Alexandru ^b   Toma Dasu, Iuliana ^a,c  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; COMPUTER MODEL; CONTROLLED STUDY; HYPOFRACTIONATED RADIOTHERAPY; HYPOXIC CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY; REOXYGENATION; SIMULATION; STEREOTACTIC BODY RADIATION THERAPY; TISSUE OXYGENATION; BIOLOGICAL MODEL; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; COMPUTER SIMULATION; HUMAN; LUNG NEOPLASMS; METABOLISM; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; RADIATION TOLERANCE;

OXYGEN;

CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; COMPUTER SIMULATION; DOSE HYPOFRACTIONATION; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; OXYGEN; OXYGEN CONSUMPTION; RADIATION TOLERANCE;

EID: 84955719943     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1061207     Document Type: Article

References (24)

1. Antonovic L, Lindblom E, Dasu A, Bassler N, Furusawa Y, Toma-Dasu I. Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy: The influence of local oxygenation changes. J Radiat Res 2014; 55: 902-11.
2. Lindblom E, Dasu A, Lax I, Toma-Dasu I. Survival and tumour control probability in tumours with heterogeneous oxygenation: A comparison between the linear-quadratic and the universal survival curve models for high doses. Acta Oncol 2014; 53: 1035-40.
3. Lindblom E, Antonovic L, Dasu A, Lax I, Wersäll P, Toma-Dasu I. Treatment fractionation for stereotactic radiotherapy of lung tumours: A modelling study of the influence of chronic and acute hypoxia on tumour control probability. Radiat Oncol 2014; 9: 149.
4. Mayles P, Nahum A, Rosenwald JC, et al. Handbook of radiotherapy physics: Theory and practice. Boca Raton, US: Taylor & Francis Group; 2007.
5. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 1981-97.
6. Dasu A, Toma-Dasu I, Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys Med Biol 2003; 48: 2829-42.
7. Konerding MA, Malkusch W, Klapthor B, van Ackern C, Fait E, Hill SA, et al. Evidence for characteristic vascular patterns in solid tumours: Quantitative studies using corrosion casts. Br J Cancer 1999; 80: 724-32.
8. Dasu A, Toma-Dasu I, Karlsson M. The effects of hypoxia on the theoretical modelling of tumour control probability. Acta Oncol 2005; 44: 563-71.
9. Toma-Dasu I, Dasu A, Brahme A. Dose prescription and optimisation based on tumour hypoxia. Acta Oncol 2009; 48: 1181-92.
10. Dasu A, Toma-Dasu I. Vascular oxygen content and the tissue oxygenation-a theoretical analysis. Med Phys 2008; 35: 539-45.
11. Toma-Dasu I, Dasu A. Modelling tumour oxygenation, reoxygenation and implications on treatment outcome. Comput Math Methods Med 2013; 2013: 141087.
12. Alper T. Cellular radiobiology. Cambridge, UK: Cambridge University Press; 1979.
13. Thames HD. An incomplete-repair model for survival after fractionated and continuous irradiations. Int J Radiat Biol Relat Stud Phys Chem Med 1985; 47: 319-39.
14. Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 2004; 59: 242-9.
15. Partridge M, Ramos M, Sardaro A, Brada M. Dose escalation for non-small cell lung cancer: Analysis and modelling of published literature. Radiother Oncol 2011; 99: 6-11.
16. Chi A, Tom WA, Fowler J, Komaki R, Nguyen NP, Mehta MP, et al. Stereotactic body radiation therapy in non-small-cell lung cancer: linking radiobiological modeling and clinical outcome. Am J Clin Oncol 2011; 34: 432-41.
17. Dasu A, Toma-Dasu I. Prostate alpha/beta revisited-an analysis of clinical results from 14 168 patients. Acta Oncol 2012; 51: 963-74.
18. Yang J, Fowler JF, Lamond JP, Lanciano R, Feng J, Brady LW. Red shell: Defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 77: 903-9.
19. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer 2004; 101: 1623-31.
20. Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumours using an accelerator: Clinical experience of the first thirty-one patients. Acta Oncol 1995; 34: 861-70.
21. Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Acta Oncol 1994; 33: 677-83.
22. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27: 3290-6.
23. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 847-52.
24. Song CW, Park H, Griffin RJ, Levitt SH. Radiobiology of stereotactic radiosurgery and stereotactic body radiation therapy. In: Levitt SH, Purdy JA, Perez CA, Poortmans P. Technical basis of radiation therapy-practical clinical applications., 5th ed. Berlin, Heidelberg: Springer-Verlag; 2012. p 51-61.